Mainboard · BSE and NSEDraft filed

Ujin Pharma Ltd. IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Mon 22 Jun 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
1,91,51,400 shares (Amount not stated in the draft)
DRHP dated Mon 22 Jun 2026, page 1
Fresh issue
1,18,69,100 shares (Amount not stated in the draft)
DRHP dated Mon 22 Jun 2026, page 1
Offer for sale
72,82,300 shares (Amount not stated in the draft)
DRHP dated Mon 22 Jun 2026, page 1
Bid dates
Not announced
Listing date
Not announced
Risk factors
77
DRHP dated Mon 22 Jun 2026, page 101
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedFri 26 Jun 2026 confirmedDRHP dated Mon 22 Jun 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Investment in Altra Agro-Chem Private Limited, our Associate Company, by way of subscription to equity shares for making it our Subsidiary₹61.72 crore
Investment in Altra Pharma-Chem Private Limited, our Associate Company, by way of subscription to equity shares for making it our Subsidiary₹21.64 crore
Repayment or pre-payment, in in part or full of certain borrowings availed by the Company from financial institutions₹25.00 crore
General Corporate PurposesNot stated in the draft
TotalNot stated in the draft

The offer for sale goes to the selling shareholders, not the company. DRHP dated Mon 22 Jun 2026, page 148

Company and promoters

As described in the DRHP

We are engaged in the distribution and supply of a diversified portfolio of solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials and nutraceuticals.

DRHP dated Mon 22 Jun 2026, page 249

Promoters

  • 3 individual promoters

DRHP dated Mon 22 Jun 2026, page 317

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group83.73%Not stated in the DRHP
Public16.28%Not stated in the DRHP

Basis: fully diluted

DRHP dated Mon 22 Jun 2026, pages 134 to 138

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Individual shareholderIndividual36,41,150Not announced
Individual shareholderIndividual36,41,150Not announced
Total offer for saleNot stated in the draft

DRHP dated Mon 22 Jun 2026, page 1

Peer comparison (as in the DRHP)

Name of the CompanyRevenue from operations, for Fiscal 2025 (₹ in million)Face Value (₹ per Share)Closing price on June 12, 2026(₹)***P/E (1)Basic EPS (In ₹) for Fiscal 2025Diluted EPS (In ₹) for Fiscal 2025RoNW (%) for Fiscal 2025 (2)NAV (₹ per share) for Fiscal 2025 (3)
Ujin Pharma Limited*Consolidated10[●][●]2.562.5111.87%24.36
Shiv ShaktiStandalone10127.004.1430.6730.6718.30143.64
Deepak NitriteConsolidated21670.132.6751.1251.1213.61%397.70
Balaji AminesConsolidated22136.343.9448.6248.628.05%622.94
Alkyl Amines Chemical LimitedStandalone21830.750.2936.4036.3513.94%273.96

Reproduced from the DRHP dated Mon 22 Jun 2026, page 180; InsightPier adds no figures

Risk factors

77 total
  1. Most revenue comes from the chemical distribution business (DRHP page 35)
  2. Reliance on imported chemical products exposes the company to supply, freight and currency disruptions (DRHP page 36)
  3. Purchases are concentrated among the top 10 suppliers (DRHP page 39)
  4. Foreign investment restrictions under Indian law may limit foreign investors (DRHP page 101)
  5. The shares have never traded publicly and their price may be volatile after listing (DRHP page 101)

All 77 risk factors, DRHP pages 34 to 102

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts